Grifols SA

OZTA

Company Profile

  • Business description

    As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

  • Contact

    Avinguda de la Generalitat, 152
    Parc de Negocis Can Sant Joan
    Sant Cugat del Valles
    Barcelona08174
    ESP

    T: +34 935712200

    E: [email protected]

    https://www.grifols.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    23,737

Stocks News & Analysis

stocks

Signs of a turnaround for undervalued ASX share

Market likes the payoff from early efforts at reining in costs.
stocks

Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?

Ashley Owen explores why investors' insatiable thirst for higher yields leads to unnecessarily complicating their portfolio.
stocks

Investing in gold miners

Exploring the commodity as prices continue to soar. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,825.1020.900.24%
CAC 408,178.5414.430.18%
DAX 4022,513.4298.60-0.44%
Dow JONES (US)44,546.08165.35-0.37%
FTSE 1008,732.4632.26-0.37%
HKSE22,620.33805.963.69%
NASDAQ20,026.7781.130.41%
Nikkei 22539,149.43312.04-0.79%
NZX 50 Index12,989.1883.200.64%
S&P 5006,114.630.44-0.01%
S&P/ASX 2008,555.8015.800.19%
SSE Composite Index3,346.7214.240.43%

Market Movers